Transcatheter Embolization And Occlusion Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Coil (Pushable Coils, Detachable Coils), Non-Coil (Flow Diverting Devices, Embolization Particles, Liquid Embolics, Other Embolization and Occlusion Devices, Accessories)), By Application (Peripheral Vascular Disease, Oncology, Neurology, Urology, Others), By Region, and By Competition, 2020-2030F

Market Overview

The Global Transcatheter Embolization And Occlusion Devices Market, valued at USD 3.52 Billion in 2024, is projected to experience a CAGR of 6.92% to reach USD 5.26 Billion by 2030. Transcatheter embolization and occlusion devices are specialized instruments for minimally invasive procedures that block or reduce blood flow to targeted anatomical regions, treating conditions like tumors and aneurysms. Market growth is driven by the increasing global prevalence of chronic diseases, particularly cancer and vascular disorders requiring advanced therapies. A rising preference for minimally invasive interventions, offering reduced patient trauma and quicker recovery, further propels demand. Continuous technological advancements enhancing device efficacy and safety also support broader adoption. According to the World Health Organization (WHO), in 2022, there were 866,136 new cases of liver cancer globally, a disease frequently managed by these devices.

A substantial challenge impeding market expansion is the scarcity of adequately trained interventional specialists. The complex nature of transcatheter procedures demands extensive expertise, limiting procedure volumes and market penetration, especially in developing healthcare systems.

Key Market Drivers

The burgeoning global prevalence of target diseases significantly underpins the expansion of the transcatheter embolization and occlusion devices market. Conditions such as cardiovascular disease, cancer, and aneurysms necessitate advanced therapeutic interventions, directly increasing the demand for effective treatment modalities. For instance, according to the Journal of the American College of Cardiology (JACC), in 2023, there were 626 million prevalent cases of cardiovascular disease globally, a substantial patient population often requiring embolization or occlusion procedures. Concurrently, the increasing adoption of minimally invasive procedures further fuels market growth. Patients and clinicians increasingly favor these techniques due to associated benefits such as reduced trauma, shorter hospital stays, and faster recovery times compared to traditional open surgeries. The ongoing shift toward less invasive interventions is evident across various specialties; according to a Deutsche Gesellschaft article, in July 2024, transcatheter heart valve procedures in Germany alone accounted for 23,752 reported TAVR procedures in 2023, demonstrating a clear preference for these advanced catheter-based methods. These dual drivers, coupled with continuous technological advancements, underpin the robust market trajectory. The financial commitment to these specialized tools reflects their integral role in modern healthcare, with over US$3.5 billion per year spent globally on embolic devices for various conditions, including tumors, internal bleeding, and aneurysms, according to Interventional News in May 2024. This substantial annual expenditure highlights the market's current scale and the ongoing investment in therapies that improve patient outcomes through minimally invasive approaches.

Download Free Sample Report

Key Market Challenges

A substantial challenge impeding the expansion of the global transcatheter embolization and occlusion devices market is the scarcity of adequately trained interventional specialists. The intricate nature of transcatheter procedures necessitates a high level of expertise and specialized training, which directly restricts the volume of procedures performed and consequently limits market penetration. This limitation is particularly pronounced in developing healthcare systems where training infrastructure may be less established.

The absence of sufficient training programs directly impacts the availability of qualified practitioners capable of utilizing these advanced devices. According to a global survey presented at RSNA 2024, 24% of respondents reported no dedicated interventional radiology training program exists in their country of practice, and less than two-thirds had graduated from an interventional radiology program. Such deficits in specialist training capacity hinder the broader adoption of transcatheter embolization and occlusion therapies, irrespective of technological advancements or increasing disease prevalence. This bottleneck slows the integration of these devices into standard clinical practice, directly stifling overall market growth by impeding patient access to these minimally invasive interventions.

Key Market Trends

The global Transcatheter Embolization and Occlusion Devices Market is experiencing significant shifts driven by advancements in technology and a growing focus on sustainable healthcare solutions.

Artificial intelligence integration is profoundly reshaping transcatheter embolization and occlusion procedures through enhanced planning, guidance, and analysis. This technology improves diagnostic precision and optimizes treatment, fostering more effective patient outcomes. A EuroAIM/EuSoMII 2024 survey of European Society of Radiology members indicated 47.9% of respondents actively employed AI systems in their clinical practice. This demonstrates a clear adoption trajectory. Clinical utility is further exemplified by a June 2025 study in the Journal of Neurointerventional Surgery, where an AI-based system, Neuro-Vascular Assist by iMed technologies, facilitated liquid embolization procedures. The system achieved 100% precision and 92.0% recall in real-time agent spread notification, prompting operator intervention in 28.3% of instances, thereby enhancing procedural safety and control. Such advancements signify AI’s expanding role in improving interventional capabilities.

The market is increasingly prioritizing sustainable and bio-resorbable device materials, driven by the dual aims of reducing long-term patient complications and environmental impact. Bio-resorbable materials provide temporary scaffolding that naturally degrades post-therapeutic function, minimizing permanent foreign body presence. This evolving preference is recognized by major clinical bodies, with European Society of Cardiology guidelines progressively acknowledging bioresorbable stents for specific patient populations. This underscores their clinical relevance and growing acceptance. Terumo Group’s commitment to sustainable practices was highlighted in April 2023, when its greenhouse gas reduction targets received approval from the Science Based Targets initiative as 1.5°C aligned. These industry efforts reflect a move towards integrating environmentally conscious and patient-centric material innovations into device development.

Segmental Insights

The Non-Coil segment is experiencing rapid growth in the Global Transcatheter Embolization And Occlusion Devices Market, primarily driven by the increasing adoption of advanced embolic agents such as microspheres and liquid embolics. These non-coil solutions offer superior control and precision during occlusion, particularly for intricate procedures like tumor embolization and managing complex vascular conditions. Their enhanced versatility, along with continuous advancements in material science and delivery systems, contributes to improved safety profiles and handling characteristics. This robust expansion is further supported by a growing preference for minimally invasive procedures, as non-coil devices facilitate shorter recovery times and reduced complication rates compared to traditional coil-based alternatives.

Regional Insights

The North American region holds a dominant position in the Global Transcatheter Embolization and Occlusion Devices Market due to several distinct factors. The region benefits from a well-established and advanced healthcare infrastructure, facilitating the widespread adoption of minimally invasive procedures for various chronic conditions such as cancer and vascular disorders. Furthermore, robust government and corporate funding actively supports research and development efforts, leading to continuous innovation in transcatheter embolization devices. The presence of a substantial base of highly trained physicians proficient in these procedures further drives their widespread utilization. Additionally, favorable reimbursement policies significantly encourage healthcare providers to offer these specialized procedures, contributing to North America's leading market share. Regulatory bodies like the U. S. Food and Drug Administration (FDA) also play a crucial role by approving innovative devices, thereby enhancing market growth and patient access to advanced treatments.

Recent Developments

• In July 2025, Medtronic initiated the PELE IDE Clinical Study, enrolling its first patient for the Onyx™ Liquid Embolic System (LES) in the peripheral vasculature. This breakthrough research aimed to evaluate the safety and effectiveness of Onyx LES for embolization of arterial hemorrhage in peripheral arteries. The study signified Medtronic's ongoing commitment to advancing embolotherapy, providing potential new solutions for managing active arterial bleeding through minimally invasive transcatheter techniques. This clinical trial was a crucial step towards expanding the applications of liquid embolic agents within the global transcatheter embolization and occlusion devices market.

• In July 2025, Boston Scientific secured expanded U.S. Food and Drug Administration (FDA) approval for its Watchman FLX and Watchman FLX Pro Left Atrial Appendage Closure (LAAC) devices. The expanded indications now included patients who had undergone catheter ablation for non-valvular atrial fibrillation. Additionally, the approval introduced a new post-implant drug regimen to the device labeling. This development reinforced the devices' role in reducing the risk of thromboembolism from the left atrial appendage, offering a safe and effective transcatheter occlusion alternative to long-term anticoagulation for a broader patient population in the global market.

• In June 2025, Penumbra, Inc. announced the U.S. Food and Drug Administration (FDA) clearance and subsequent launch of its Ruby® XL System. This new product represented an advancement in transcatheter embolization devices, offering the longest, largest, and softest coil available in the market. The Ruby XL System, including Ruby XL, POD® XL, and Packing Coil XL, was engineered to facilitate more efficient vascular embolization, potentially reducing radiation exposure for patients and optimizing procedural outcomes, particularly in large vessel and high-flow embolization cases. The introduction of these coils provided physicians with expanded options for peripheral embolization procedures, directly impacting the global transcatheter embolization and occlusion devices market.

• In May 2024, Merit Medical Systems received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Siege vascular plug and concurrently launched its Bearing non-spherical polyvinyl alcohol (nsPVA) Express prefilled syringe in the USA and Australia. These additions significantly augmented Merit Medical's embolics portfolio, which already includes a comprehensive array of microsphere, particle, and gelatine foam products. The Siege vascular plug features a deliverable and recapturable design, enabling precise placement and achieving rapid vessel occlusion. These developments directly enhanced the range of transcatheter embolization and occlusion devices available for various minimally-invasive procedures.

Key Market Players

• Boston Scientific Corp
• Terumo Corp
• Medtronic PLC
• DePuy Synthes Inc
• Stryker Corp
• Cordis Corp
• Abbott Laboratories Inc
• Pfizer Inc
• Sirtex Medical Inc
• Nordion Inc

Report Scope:

In this report, the Global Transcatheter Embolization And Occlusion Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Transcatheter Embolization And Occlusion Devices Market, By Product:

o   Coil

o   Non-Coil

• Transcatheter Embolization And Occlusion Devices Market, By Application:

o   Peripheral Vascular Disease

o   Oncology

o   Neurology

o   Urology

o   Others

• Transcatheter Embolization And Occlusion Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Transcatheter Embolization And Occlusion Devices Market.

Available Customizations:

Global Transcatheter Embolization And Occlusion Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Transcatheter Embolization And Occlusion Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]